{"id":609551,"date":"2022-07-26T17:58:02","date_gmt":"2022-07-26T17:58:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=609551"},"modified":"2022-07-26T17:58:02","modified_gmt":"2022-07-26T17:58:02","slug":"the-companion-diagnostics-development-services-market-is-anticipated-to-grow-at-a-cagr-of-over-10-till-2035-claims-roots-analysis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-companion-diagnostics-development-services-market-is-anticipated-to-grow-at-a-cagr-of-over-10-till-2035-claims-roots-analysis_609551.html","title":{"rendered":"The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis"},"content":{"rendered":"
Given the various challenges associated with co-development of companion diagnostics and drug \/ therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies<\/div>\n

Roots Analysis<\/strong> has announced the addition of “Companion Diagnostics<\/a> Development Services Market<\/strong> (2nd<\/sup> Edition), 2022-2035<\/strong>” report to its list of offerings.<\/p>\n

 <\/p>\n

The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.  <\/p>\n

To order this 660+ page report, which features 190+ figures and 260+ tables, please visit <\/em><\/strong>https:\/\/www.rootsanalysis.com\/reports\/view_document\/companion-diagnostics-services\/297.html<\/em><\/strong><\/a><\/p>\n

                           <\/p>\n

Key Market Insights <\/strong><\/p>\n

 <\/strong><\/p>\n

Over 150 companies claim to offer companion diagnostics development services, globally<\/strong><\/p>\n

Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers.<\/p>\n

 <\/p>\n

Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization<\/strong><\/p>\n

Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery \/ identification. Further, NGS is the most popular technique, employed by over 100 service providers.<\/p>\n

 <\/strong><\/p>\n

Over 90 companies are actively involved in companion diagnostics development<\/strong><\/p>\n

Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics.<\/p>\n

 <\/p>\n

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 <\/strong><\/p>\n

Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders.<\/p>\n

 <\/p>\n

 <\/p>\n

North America is expected to capture ~60% share in the companion diagnostics services market by 2035<\/strong><\/p>\n

Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035,  are generated from companion diagnostics development projects for cancer indications.<\/p>\n

 <\/p>\n

 <\/em><\/strong><\/p>\n

To request a sample copy \/ brochure of this report, please visit<\/em><\/strong> https:\/\/www.rootsanalysis.com\/reports\/companion-diagnostics-services\/request-sample.html <\/em><\/strong><\/a><\/p>\n

 <\/strong><\/p>\n

Key Questions Answered<\/strong><\/p>\n